An Audience With | Published:

Morgan Sheng

Nature Reviews Drug Discovery volume 17, pages 8889 (2018) | Download Citation

In 2006, Genentech re-entered into the neuroscience fray by partnering with AC Immune to develop novel Alzheimer disease treatments. A year and half later, Morgan Sheng joined the biotech firm as Vice President of Neuroscience, and was tasked with putting together a plan to eke new drug candidates out of emerging science. Ten years on, the firm's neuroscience pipeline includes three Alzheimer drugs, one amyotrophic lateral sclerosis drug, one pain drug and a number of preclinical candidates. Sheng spoke with Asher Mullard about his continued faith in the amyloid hypothesis, the case for novel Alzheimer disease targets, the promise of emerging Parkinson disease genetics and the overlap between psychiatric disease and neurodegeneration.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrd.2017.271

Authors

    Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing